Healthcare / Medical DistributionTaiwan
$70.10
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-35.5M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.2B
P/E
15.2x
↓EV/EBITDA
7.5x
↓ROE
8.8%
↑Gross Margin
21.3%
↓Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.9%
FCF CAGR
—
FCF margin
-16.5%
FCF / Net income
-1.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.79B · net income $805.9M · FCF $-1.45B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.79B | $8.79B | $8.54B | $8.23B | $7.19B |
| Net Income | $805.9M | $805.9M | $771.3M | $746.6M | $667.5M |
| EBITDA | $1.53B | $1.53B | $1.50B | $1.43B | $1.20B |
| EPS | — | — | 4.41 | 4.26 | 3.81 |
| Gross Margin | 21.3% | 21.3% | 20.9% | 20.3% | 21.1% |
| Operating Margin | 8.3% | 8.3% | 8.8% | 8.5% | 8.6% |
| Net Margin | 9.2% | 9.2% | 9.0% | 9.1% | 9.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.16 | 0.17 | 0.10 |
| Current Ratio | 1.71 | 1.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.45B | $-1.45B | $2.35B | $-35.5M | $464.6M |
| Returns | |||||
| ROE | 8.8% | 8.8% | 8.6% | 8.7% | 8.1% |
| Valuation | |||||
| P/E | 15.21 | 15.21 | 18.50 | 18.79 | 15.31 |
| EV/EBITDA | 7.54 | 7.54 | 7.66 | 9.01 | 7.12 |
| P/B | 1.33 | 1.33 | 1.59 | 1.63 | 1.25 |
| Growth & Yield | |||||
| Revenue Growth | 2.9% | 2.9% | 3.7% | 14.6% | — |
| EPS Growth | — | — | 3.4% | 11.9% | — |
| Dividend Yield | 6.1% | 6.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.2%
Start / end P/E
n/dx → n/dx
EPS bridge
4.41 → n/d
Residual
-14.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.